**Core Concept**
Certolizumab is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) and is used in the treatment of autoimmune diseases characterized by inflammation.

**Why the Correct Answer is Right**
Certolizumab works by binding to TNF-alpha, preventing its interaction with TNF receptors on the surface of immune cells. This reduces inflammation and slows disease progression in conditions such as Crohn's disease, rheumatoid arthritis, and psoriatic arthritis. The mechanism of action is similar to other TNF-alpha inhibitors like infliximab and adalimumab. By blocking the action of TNF-alpha, certolizumab reduces the recruitment of immune cells to the site of inflammation, thereby decreasing the symptoms of these diseases.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because certolizumab is not used in the treatment of type 2 diabetes mellitus. While some TNF-alpha inhibitors have been associated with an increased risk of new-onset diabetes, certolizumab is not indicated for this condition.
**Option B:** This option is incorrect because certolizumab is not used in the treatment of hypertension. While some studies have suggested a potential link between TNF-alpha levels and blood pressure regulation, certolizumab is not indicated for the treatment of hypertension.
**Option C:** This option is incorrect because certolizumab is not used in the treatment of acute coronary syndromes. While some studies have suggested a potential link between inflammation and cardiovascular disease, certolizumab is not indicated for the treatment of acute coronary syndromes.

**Clinical Pearl / High-Yield Fact**
It's worth noting that certolizumab has a unique feature of being a PEGylated Fab' fragment, which allows it to have a longer half-life and reduced immunogenicity compared to other monoclonal antibodies.

**Correct Answer:** C.